Low rates, M&A spur flood of pharma debt deals
February 05, 2015 at 15:01 PM EST
NEW YORK, Feb 5 (IFR) - Merck & Co's US$8bn jumbo bond is just the tip of the iceberg of debt supply from the healthcare sector in the months ahead with brand names like Novartis and Pfizer set to compete for investor cash.
